RJFSA
FENC icon

Raymond James Financial Services Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Raymond James Financial Services Advisors’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-28,325
Closed -$211K – 3215
2020
Q4 		$211K Buy
28,325
+3,325
+13% +$25.3K ﹤0.01% 2683
2020
Q3 		$152K Buy
+25,000
New +$176K ﹤0.01% 2608

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Raymond James Financial Services Advisors's FENC Position: Q1 2021 in Review

Raymond James Financial Services Advisors sold out of Fennec Pharmaceuticals (FENC) in Q1 2021, closing a stake of 28,325 shares — an estimated $211K sold.

Raymond James Financial Services Advisors first reported a position in FENC in Q3 2020 and held it in 2 quarters. The position peaked at $211K in Q4 2020. 52 funds tracked by Wall St. Rank hold FENC as of Q1 2021.

  • Raymond James Financial Services Advisors reported no remaining Fennec Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 28,325 Fennec Pharmaceuticals shares in Q1 2021, an estimated $211K.
  • Raymond James Financial Services Advisors first reported a position in Fennec Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Fennec Pharmaceuticals position peaked at $211K in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2021, filed 14 May 2021.